About Histogen (HSTO)

Histogen Inc. (HSTO) is a biotech company that specializes in developing innovative therapies to address unmet needs in the field of regenerative medicine. The company is focused on harnessing the power of human cells and proteins to stimulate the body's natural regenerative processes. Histogen's flagship product is a proprietary liquid formula called HST-001, which is designed to promote hair growth in individuals with androgenic alopecia, also known as male pattern baldness. The product is currently in clinical trials and has shown promising results. Histogen is also working on developing therapies for other indications, including skin rejuvenation and joint regeneration.

As of the latest available market data, Histogen Inc. has a market capitalization of approximately $100 million. The company's stock, traded under the ticker symbol HSTO, has had a mixed performance in the market. Over the past 52 weeks, the stock has traded in a range of $2.50 to $10.00 per share. The stock's day range can vary depending on market conditions, but it has typically shown moderate volatility. Trading volume for Histogen Inc. tends to be relatively low, reflecting the company's early stage of development and the limited number of shares outstanding. The stock is listed on the NASDAQ exchange.